FDA grants priority review to Roche’s Esbriet (pirfenidone) for unclassifiable interstitial lung disease

2021-01-21

Helpful links

Finance information tool

Ad hoc announcements

Services

Investor Relations team

Subscribe to Roche Investor updates

additional materials

download 200121_IR_FDA_priority_review_Esbriet_EN

PDF

InvestorsInvestor updates

stay updated

get the latest news and updates to your inbox.